NYSE - Nasdaq Real Time Price • USD
GSK plc (GSK)
At close: 3:59 PM EDT
After hours: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 4 | 4 |
| Avg. Estimate | 0.91 | 0.94 | 3.96 | 4.49 |
| Low Estimate | 0.91 | 0.94 | 3.91 | 4.4 |
| High Estimate | 0.91 | 0.94 | 4.01 | 4.55 |
| Year Ago EPS | 0.9 | 0.97 | 3.86 | 3.96 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 6 | 6 |
| Avg. Estimate | 8.91B | 9.46B | 39.31B | 41.93B |
| Low Estimate | 8.64B | 9.36B | 38.94B | 41.35B |
| High Estimate | 9.18B | 9.56B | 39.81B | 42.49B |
| Year Ago Sales | 8.45B | 8.99B | 37.7B | 39.31B |
| Sales Growth (year/est) | 5.50% | 5.20% | 4.20% | 6.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.82 | 0.87 | 1.14 | 0.76 |
| EPS Actual | 0.9 | 0.97 | 1.28 | 0.72 |
| Difference | 0.08 | 0.1 | 0.14 | -0.04 |
| Surprise % | 9.80% | 11.50% | 12.30% | -5.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.91 | 0.94 | 3.96 | 4.49 |
| 7 Days Ago | 0.91 | 0.94 | 3.96 | 4.49 |
| 30 Days Ago | 0 | 0 | 4.03 | 4.55 |
| 60 Days Ago | 0 | 0 | 3.99 | 4.45 |
| 90 Days Ago | 0 | 0 | 4.04 | 4.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | GSK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 1.10% | -- | -- | 2.60% |
| Next Qtr. | -3.10% | -- | -- | 13.40% |
| Current Year | 2.60% | -- | -- | 5.20% |
| Next Year | 13.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 4.80% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -2.43% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Guggenheim: Neutral to Buy | 3/4/2024 |
| Initiated | Morgan Stanley: Equal-Weight | 1/23/2024 |
| Upgrade | Jefferies: Hold to Buy | 1/3/2024 |
Related Tickers
SNY Sanofi
49.36
+5.90%
AZN AstraZeneca PLC
75.03
+5.38%
BMY Bristol-Myers Squibb Company
44.68
-8.56%
NVS Novartis AG
99.04
+0.70%
MRK Merck & Co., Inc.
130.67
+2.89%
GILD Gilead Sciences, Inc.
65.27
-2.70%
OGN Organon & Co.
18.43
-1.52%
RHHBY Roche Holding AG
30.00
-1.77%
AMGN Amgen Inc.
269.38
-1.33%
ABBV AbbVie Inc.
167.25
-0.33%